Leading the Way in Life Science Technologies

GEN Exclusives

More »

GEN News Highlights

More »
May 21, 2012

Ventana Licenses Gen-Probe IP for Measuring ERG Protein in Prostate Cancer

  • Roche’s Ventana Medical Systems co-exclusively sublicensed IP from Gen-Probe granting the firm in vitro diagnostic rights relating to the immunohistochemical measurement of ERG protein expression in prostate tissue. Ventana says the licensed IP complements its existing co-exclusive sublicense to IP covering in situ hybridization measurements of ETS gene rearrangements (including ERG gene rearrangements) in tissue.

    Ventana specializes in the development and manufacture of instruments and reagents for automating tissue processing and slide staining in cancer diagnostics. The firm’s ERG assays for its BenchMark line of automated instrumentation include a global ERG IVD test for measuring ERG via immunohistochemical staining and a CE-marked IVD assay for measuring ERG gene rearrangements using Quantum Dot (FISH). Multivariate assays for novel clinical assays are also in development.

    “We believe ERG testing by IHC and ISH will play an important role in novel diagnostic, prognostic, and predictive tests for prostate cancer,” comments Mara G. Aspinall, Ventana president. “This license gives us a unique position for this important biomarker as we see the opportunity to incorporate the ERG marker into Ventana assays.”

Related content

Be sure to take the GEN Poll

Scientifically Studying Ecstasy

MDMA (commonly known as the empathogen “ecstasy”) is classified as a Schedule 1 drug, which is reserved for compounds with no accepted medical use and a high abuse potential. Two researchers from Stanford, however, call for a rigorous scientific exploration of MDMA's effects to identify precisely how the drug works, the data from which could be used to develop therapeutic compounds.

Do you agree that ecstasy should be studied for its potential therapeutic benefits?

More »